semaglutide ed Semaglutide: The benefits and risks of the weight-loss wonder drug sweeping America Health Rounds: Novo Nordisk's semaglutide

Image Credit: Studio Romantic / Shutterstock.com In a recent study published in the Cardiovascular DiabetologyEndocrinology Reports , researchers evaluated the long-term cardiovascular safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in high-risk populations

Dr Hoe Ying Min, medical director at Bay Aesthetics Clinic And Medispa, said she has observed a rise in interest in weight loss medications

TRIUMPH-1 trajectory (80 weeks + extension): Week 80: 28.3% average weight loss (2,339 patients) 104-week extension (BMI 35 subgroup): 30.3% average weight loss Weight loss does not plateau at 80 weeks it continues in longer treatment The TRIUMPH-1 104-week extension is the most important long-term efficacy signal we have

Article summary AI generated Postprandial hypoglycemia (PH) is a complex and significant complication following upper gastrointestinal (GI) surgery, particularly affecting patients' quality of life and health outcomes due to its multifactorial pathophysiology